Work

276O Pooled analysis of patient (pt)-reported quality of life (QOL) in the MONALEESA (ML)-2, -3, and -7 trials of ribociclib (RIB) plus endocrine therapy (ET) to treat hormone receptor–positive, HER2-negative (HR+/HER2−) advanced breast cancer (ABC)

Year: 2020

Type: article

Source: Annals of Oncology

DOI: 10.1016/j.annonc.2020.08.378

Authors: P.A. Fasching, A. Bardia, A. Nusch, G. Jerusalem, A. Chan, N. El Saghir, E. Alba, S-A. Im, W. Janni, D. Chandiwana, B. Lanoue, A. Thuerigen, A. Gaur, N. Harbeck

Institutions: Universitätsklinikum Erlangen, Massachusetts General Hospital, Centre Hospitalier Universitaire de Liège, American University of Beirut Medical Center, Hospital Clínico Universitario Virgen de la Victoria, Seoul National University, Seoul National University Hospital, University Hospital Ulm, Novartis (United States), Novartis (Switzerland), Novartis (India), Ludwig-Maximilians-Universität München

Language: English

Topic: Advanced Breast Cancer Therapies

Subfield: Pulmonary and Respiratory Medicine

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: bronze

OpenAlex ID: W3087819517

FWCI: 0.705

Cites:

Cited by: 7

Related to: 10